Literature DB >> 20484410

cAMP-dependent activation of mammalian target of rapamycin (mTOR) in thyroid cells. Implication in mitogenesis and activation of CDK4.

Sara Blancquaert1, Lifu Wang, Sabine Paternot, Katia Coulonval, Jacques E Dumont, Thurl E Harris, Pierre P Roger.   

Abstract

How cAMP-dependent protein kinases [protein kinase A (PKA)] transduce the mitogenic stimulus elicited by TSH in thyroid cells to late activation of cyclin D3-cyclin-dependent kinase 4 (CDK4) remains enigmatic. Here we show in PC Cl3 rat thyroid cells that TSH/cAMP, like insulin, activates the mammalian target of rapamycin (mTOR)-raptor complex (mTORC1) leading to phosphorylation of S6K1 and 4E-BP1. mTORC1-dependent S6K1 phosphorylation in response to both insulin and cAMP required amino acids, whereas inhibition of AMP-activated protein kinase and glycogen synthase kinase 3 enhanced insulin but not cAMP effects. Unlike insulin, TSH/cAMP did not activate protein kinase B or induce tuberous sclerosis complex 2 phosphorylation at T1462 and Y1571. However, like insulin, TSH/cAMP produced a stable increase in mTORC1 kinase activity that was associated with augmented 4E-BP1 binding to raptor. This could be caused in part by T246 phosphorylation of PRAS40, which was found as an in vitro substrate of PKA. Both in PC Cl3 cells and primary dog thyrocytes, rapamycin inhibited DNA synthesis and retinoblastoma protein phosphorylation induced by TSH and insulin. Although rapamycin reduced cyclin D3 accumulation, the abundance of cyclin D3-CDK4 complexes was not affected. However, rapamycin inhibited the activity of these complexes by decreasing the TSH and insulin-mediated stimulation of activating T172 phosphorylation of CDK4. We propose that mTORC1 activation by TSH, at least in part through PKA-dependent phosphorylation of PRAS40, crucially contributes to mediate cAMP-dependent mitogenesis by regulating CDK4 T172-phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484410      PMCID: PMC2903905          DOI: 10.1210/me.2010-0087

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  97 in total

1.  Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002.

Authors:  G J Brunn; J Williams; C Sabers; G Wiederrecht; J C Lawrence; R T Abraham
Journal:  EMBO J       Date:  1996-10-01       Impact factor: 11.598

Review 2.  Multiple facets of the modulation of growth by cAMP.

Authors:  P P Roger; S Reuse; C Maenhaut; J E Dumont
Journal:  Vitam Horm       Date:  1995       Impact factor: 3.421

3.  Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family.

Authors:  H B Jefferies; C Reinhard; S C Kozma; G Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

4.  In rat hepatocytes glucagon increases mammalian target of rapamycin phosphorylation on serine 2448 but antagonizes the phosphorylation of its downstream targets induced by insulin and amino acids.

Authors:  Isabelle Mothe-Satney; Nadine Gautier; Charlotte Hinault; John C Lawrence; Emmanuel Van Obberghen
Journal:  J Biol Chem       Date:  2004-08-02       Impact factor: 5.157

5.  Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin.

Authors:  J Nourse; E Firpo; W M Flanagan; S Coats; K Polyak; M H Lee; J Massague; G R Crabtree; J M Roberts
Journal:  Nature       Date:  1994-12-08       Impact factor: 49.962

6.  Activation of cyclin-dependent kinase 4 (cdk4) by mouse MO15-associated kinase.

Authors:  M Matsuoka; J Y Kato; R P Fisher; D O Morgan; C J Sherr
Journal:  Mol Cell Biol       Date:  1994-11       Impact factor: 4.272

7.  Mitogenic effects of thyrotropin and adenosine 3',5'-monophosphate in differentiated normal human thyroid cells in vitro.

Authors:  P Roger; M Taton; J Van Sande; J E Dumont
Journal:  J Clin Endocrinol Metab       Date:  1988-06       Impact factor: 5.958

8.  Dissociation of cAMP-stimulated mitogenesis from activation of the mitogen-activated protein kinase cascade in Swiss 3T3 cells.

Authors:  D J Withers; S R Bloom; E Rozengurt
Journal:  J Biol Chem       Date:  1995-09-08       Impact factor: 5.157

9.  Stimulation by thyrotropin and cyclic AMP of the proliferation of quiescent canine thyroid cells cultured in a defined medium containing insulin.

Authors:  P P Roger; P Servais; J E Dumont
Journal:  FEBS Lett       Date:  1983-07-04       Impact factor: 4.124

10.  cAMP- and rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells.

Authors:  L M Graves; K E Bornfeldt; G M Argast; E G Krebs; X Kong; T A Lin; J C Lawrence
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

View more
  28 in total

Review 1.  The regulation of autophagy - unanswered questions.

Authors:  Yongqiang Chen; Daniel J Klionsky
Journal:  J Cell Sci       Date:  2011-01-15       Impact factor: 5.285

2.  Prostaglandin E2 activates the mTORC1 pathway through an EP4/cAMP/PKA- and EP1/Ca2+-mediated mechanism in the human pancreatic carcinoma cell line PANC-1.

Authors:  Hui-Hua Chang; Steven H Young; James Sinnett-Smith; Caroline Ei Ne Chou; Aune Moro; Kathleen M Hertzer; Oscar Joe Hines; Enrique Rozengurt; Guido Eibl
Journal:  Am J Physiol Cell Physiol       Date:  2015-08-26       Impact factor: 4.249

3.  Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.

Authors:  Roberta Malaguarnera; Kuen-Yuan Chen; Tae-Yong Kim; Jose M Dominguez; Francesca Voza; Bin Ouyang; Sushil K Vundavalli; Jeffrey A Knauf; James A Fagin
Journal:  J Clin Endocrinol Metab       Date:  2014-07-16       Impact factor: 5.958

4.  Wnt-independent role of β-catenin in thyroid cell proliferation and differentiation.

Authors:  Ana Sastre-Perona; Pilar Santisteban
Journal:  Mol Endocrinol       Date:  2014-03-19

5.  mTOR pathway is activated by PKA in adrenocortical cells and participates in vivo to apoptosis resistance in primary pigmented nodular adrenocortical disease (PPNAD).

Authors:  Cyrille de Joussineau; Isabelle Sahut-Barnola; Frédérique Tissier; Typhanie Dumontet; Coralie Drelon; Marie Batisse-Lignier; Igor Tauveron; Jean-Christophe Pointud; Anne-Marie Lefrançois-Martinez; Constantine A Stratakis; Jérôme Bertherat; Pierre Val; Antoine Martinez
Journal:  Hum Mol Genet       Date:  2014-05-27       Impact factor: 6.150

6.  Activation of mTORC1 is essential for β-adrenergic stimulation of adipose browning.

Authors:  Dianxin Liu; Marica Bordicchia; Chaoying Zhang; Huafeng Fang; Wan Wei; Jian-Liang Li; Adilson Guilherme; Kalyani Guntur; Michael P Czech; Sheila Collins
Journal:  J Clin Invest       Date:  2016-03-28       Impact factor: 14.808

7.  FOXO1 controls thyroid cell proliferation in response to TSH and IGF-I and is involved in thyroid tumorigenesis.

Authors:  Miguel A Zaballos; Pilar Santisteban
Journal:  Mol Endocrinol       Date:  2012-11-16

8.  Thyroid Nodules in Type 2 Diabetes Mellitus.

Authors:  Hong-Mei Zhang; Qi-Wen Feng; Yi-Xin Niu; Qing Su; Xia Wang
Journal:  Curr Med Sci       Date:  2019-07-25

9.  Loss of DP1 Aggravates Vascular Remodeling in Pulmonary Arterial Hypertension via mTORC1 Signaling.

Authors:  Yuhu He; Caojian Zuo; Daile Jia; Peiyuan Bai; Deping Kong; Di Chen; Guizhu Liu; Juanjuan Li; Yuanyang Wang; Guilin Chen; Shuai Yan; Bing Xiao; Jian Zhang; Lingjuan Piao; Yanli Li; Yi Deng; Bin Li; Philippe P Roux; Katrin I Andreasson; Richard M Breyer; Yunchao Su; Jian Wang; Ankang Lyu; Yujun Shen; Ying Yu
Journal:  Am J Respir Crit Care Med       Date:  2020-05-15       Impact factor: 21.405

10.  The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.

Authors:  Sabine Paternot; Bianca Colleoni; Xavier Bisteau; Pierre P Roger
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.